Use of Vasopressin Following the Fontan Operation

2016-11-30 15:45:40 | BioPortfolio


The purpose of this study is to determine whether Vasopressin following the Fontan operation will decrease chest tube output and duration.


A pilot and subsequently a multicenter, randomized, double blinded clinical trial to evaluate the use of vasopressin following the Fontan operation.

Phase one of the study will be a single center pilot study and will be conducted at Advocate Children's Hospital, Oak Lawn IL. This will be a randomized and double blinded. Ten patients will be enrolled with five patients as control group and five receiving Vasopressin. The same protocol will be used for both phases of the study. Vasopressin levels will be obtained just prior to initiation of Vasopressin in the pilot study. Safety and effect size will be evaluated after this pilot study.

The multicenter study will be phase two and will be conducted in the cardiac operating rooms and cardiac intensive care unit (CVICU) of 7 pediatric cardiovascular programs in the United States. The investigators will be enrolling 12 subjects undergoing the Fontan operation from each participating institution. Six patients will be randomly assigned to receive Vasopressin while six will receive placebo.

A total of 84 patients undergoing the Fontan operation will be included in the study and randomized to one of the two treatment groups.

Group 1 will include 42 subjects who will receive the treatment drug (Vasopressin) for 48 hours following the Fontan operation. Group 2 will include 42 subjects who will receive placebo (normal saline) and will serve as a control group.

Drug administration protocol:

Vasopressin at a dose of 0.3 mU/kg/min will be started on subjects in the study group while coming off cardiopulmonary bypass. The dose of Vasopressin will be titrated in the CVICU to a maximum of 0.5 mU/kg/min according to blood pressure and clinical perfusion. The drip will eventually be titrated down to 0.3 mU/kg/min and from that dose will be discontinued 48 hours after arrival in the CVICU.

The placebo group will be receiving normal saline and that can also be titrated at the same 'dose' of the Vasopressin group. The treating physician will be blinded.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Pleural Effusion


Vasopressin, Normal Saline


Advocate Children's Hospital
Oak Lawn
United States


Not yet recruiting


Advocate Health Care

Results (where available)

View Results


Published on BioPortfolio: 2016-11-30T15:45:40-0500

Clinical Trials [821 Associated Clinical Trials listed on BioPortfolio]

Pleural Effusion Following Cardiac Surgery: Prevalence, Risk Factors and Clinical Features

Pleural effusion is a common complication of cardiac surgery. The aim of this study was to determine the prevalence, characteristics and determinants of clinically significant pleural effu...

Ultrasound Estimation of Pleural Effusion in the Sitting Patients

The aim of this study is the feasibility assessment of a simple and affordable model for the quantification of Pleural Effusion through thoracic Ultra Sounds images. Two US scans will be p...

Continuous Positive Airway Pressure on Tuberculosis Pleural Effusion

Tuberculosis (TB) remains as an important public health problem worldwide. Pleural tuberculosis is the most prevalent form of extrapulmonary presentation in immunocompetent patients. ...

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

This is a phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy. Second...

Talc in Treating Patients With Malignant Pleural Effusion

RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion. PURPOSE:...

PubMed Articles [6438 Associated PubMed Articles listed on BioPortfolio]

Use of indwelling pleural catheters for the definitive treatment of malignant pleural effusion.

To evaluate the safety and feasibility of the use of indwelling pleural catheters (IPCs) in patients with malignant pleural effusion (MPE).

Mortality Following Catheter Drainage Versus Thoracentesis in Cirrhotic Patients with Pleural Effusion.

Pleural effusion is an abnormal collection of body fluids that may cause related morbidity or mortality in cirrhotic patients. There are insufficient data to determine the optimal method of drainage, ...

The case for performing pleural biopsies for the aetiological diagnosis of exudates. Yes.

Pleural biopsies are especially indicated in the following circumstances: a) inconclusive pleural fluid analysis and negative sputum study, if adenosine deaminase (ADA) levels are unavailable; b) susp...

Pleuroperitoneal communication: pleural effusion subsequent to the initiation of peritoneal dialysis, about a case.

We report the case of a patient with pleural effusion occurring after initiation of a peritoneal dialysis. This phenomenon is favoured by the existence of a pleuroperitoneal communication. The latter ...

Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion.

Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays an important role in intracellular reactive oxygen species generation. Recently, Romo1 has been suggested to have diagnostic a...

Medical and Biotech [MESH] Definitions

Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.

Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.

Surgical creation of an opening (stoma) into the chest cavity for drainage; used in the treatment of pleural effusion, pneumothorax, hemothorax and empyema.

A tumorlike condition characterized by SMOOTH MUSCLE and ENDOTHELIUM proliferation of LYMPHATIC VESSELS and LYMPH NODES in the MEDIASTINUM and retroperitoneum, also in the lung. It may be manifested by chylous PLEURAL EFFUSION and ASCITES.

A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.

More From BioPortfolio on "Use of Vasopressin Following the Fontan Operation"

Quick Search

Searches Linking to this Trial